All News

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

Research showed a survival improvement in adolescent and young adult cancer survival after the Dependent Care Expansion allowed patients to be on their parents’ insurance until the age of 26.

Hospice care can be a valuable resource for patients with late-stage cancer who want to improve the quality of the rest of their life.

Sometimes I feel lazy and berate myself instead of admitting that I am ill.

Patients born outside of the U.S. may have improved liver cancer survival rates compared with U.S.-born patients, although more research is needed to determine what may be driving this effect, research showed.

During an uncertain time, Missy Bean-Tanner, RN, brings inner peace and reassurance. She will jump into anything if she knows it will help her patients.

The National Comprehensive Cancer Network updated its recommendations to include Krazati for patients with KRAS G12-mutant pancreatic cancer.

“Nobody’s going to fight for your life the way you’re going to fight for your life,” Hodgkin’s lymphoma survivor, Paula Ngon, told CURE®.

As a mom, I have the “worry gene,” though it got much worse when my daughter was diagnosed with cancer.

Watch Dr. Jyoti Malhotra and Ken Culver answer questions about the future of the disease during the CURE® Educated Patient® Lung Cancer Summit.

It is that one-to-one communication that allows Kimberly Rosencrance, B.S.N., RN, OCN, to excel as an oncology nurse.

Campaigns such as #BrewStacheStrong and Melesa’s Wings are uniting brewers and craft beer aficionados as they raise funds and awareness for cancer.

For the past nine years, I’ve struggled with waves of overwhelming fear of cancer recurrence. I knew I had an issue, but until recently, wasn’t aware of how much fear was affecting my life.

Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced non-small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

I was diagnosed with cancer five years ago, and am extremely grateful for the people I met along the way.

The costs related to a cancer diagnosis go beyond treatment, reflecting the altered participation in the workforce for adolescents and young adults.

With each hike I complete, I feel empowered and reminded that breast cancer — and lingering lymphedema — cannot keep me down.

The drug combination of Lonsurf plus Avastin improved survival in patients with pretreated, metastatic, refractory colorectal cancer, according to recently published study findings.

Watch Dr. Erminia Massarelli, from City of Hope National Medical Center, discuss advancements in early-stage non-small cell disease during the CURE® Educated Patient® Lung Cancer Summit.

Among the extraordinary collection of givers are singular nurses who stand above the rest like a beacon guiding the profession toward its highest order. Anthony “Tony” Reynolds, RN, of ARH Cancer Center is one such nurse.

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

After being diagnosed with a rare form of cancer — and seeing a clinician who did not know how to treat me — I learned the importance of asking questions to my providers and advocating for myself

Watch Dr. Ed Kim, Dr. Jyoti Malhotra and Terri Conneran answer questions about targeted therapy during the CURE® Educated Patient® Lung Cancer Summit.

For a young girl dying of cancer, whose mother had other children at home to take care of, Sobha Akkar, B.S.N., RN, OCN, became a motherly figure.

From music to poetry and dynamic storytelling, the first installment of CURE®’s Open Mic Showcase highlights the talents of patients and survivors of cancer.

The FDA approval of Epkinly also includes a subset of patients with indolent lymphoma-related DLBCL and those with high-grade B-cell lymphoma after two or more systemic therapies.

I hated the way that hormone drugs made me feel, so I spoke with my loved ones and oncology team and made the difficult decision to stop.